Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a solid tumour that has spread to other parts of the body or cannot be surgically removed, and has continued to grow or spread after at least one previous treatment.
- People whose tumour has a specific gene change called a PIK3CA activating mutation, found through a test of tumour tissue or a blood test.
- People who have at least one tumour that can be measured or assessed using standard imaging criteria (called RECIST v1.1).
- People who are generally well enough to carry out light activity and care for themselves, based on a standard health rating scale (ECOG score of 0 or 1).
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements.
- For certain parts of the trial (Parts B and C only): People with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer that has spread or cannot be surgically removed with the goal of cure, and who have already received at least one CDK4/6 inhibitor treatment and at least one anti-oestrogen therapy.
Who may not be able to join:
- People who have had a different type of cancer (solid tumour or blood cancer) within the past two years.
- People who have brain or spinal metastases causing symptoms, or whose cancer has spread to the central nervous system and has not been treated or is not well controlled.
- People who have been diagnosed with Type 1 diabetes, or who have Type 2 diabetes that is not well controlled.
- People who have received any cancer treatment (standard or experimental) within 14 days before the start of the trial treatment.
- People who still have side effects from previous cancer treatments that have not returned to their normal baseline levels (hair loss and nerve-related symptoms are exceptions to this rule).
- People who have had radiation therapy to areas other than the target tumour within 14 days before the start of the trial treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-617-383-4993
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B; Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B; Select the Recommended Phase 2 Dose(s) (RP2D) in Part B to be further explored in Part C (combination therapy expansion); Evaluate efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.